



Synthelis®

SYNTHELIS, the French expert in cell-free biomanufacturing technology, announced the signature on 25 November 2023 of an agreement to acquire the company from Vincent Poher, a Grenoble-based entrepreneur specializing in in-vitro diagnostics. Synthelis has thus become SYNTHELIS BIOTECH since that date.

This agreement marks a strategic turning point for Synthelis, opening up new prospects for growth in the dynamic cell-free biomanufacturing market. Synthelis Biotech is constantly seeking to innovate, in particular through the development of new products and services, to strengthen its ability to offer quality products to better meet the needs of its customers and the industry.

Bruno Tillier, the new Chief Operating Officer of Synthelis Biotech, and Vincent Poher, the new President, will combine their skills and resources to fully support the new entity's growth strategy. Driven by shared values and a common vision, they are jointly committed to further expanding the use of cell-free technology to accelerate research through high-throughput protein expression and the production of vaccine and drug candidates.



“

Bruno Tillier, Chief Operating Officer, comments:

"Vincent Poher's acquisition of Synthelis breathes new life into the company I co-founded with Prof. Jean-Luc Lenormand almost 13 years ago. We absolutely needed it to reveal the full potential of what we had developed over the years. With the expertise of our team, now enriched by Vincent's skills, we are ready to take our company to new heights. I'm delighted for our customers, our partners, our team and, more broadly, for the entire French industry, which is in search of innovation."

”

“

Vincent Poher, CEO, announces:

"The strength of SYNTHELIS' proprietary technology and know-how, the clarity of Bruno Tillier's vision of the developments needed to move into biomanufacturing, and the eminence of SYNTHELIS' recurring customers in the pharmaceutical and life sciences fields convinced me that SYNTHELIS had all the assets to become the champion of cell-free technology that Europe needs. SANOFI's recent decision to select SYNTHELIS BIOTECH in the European iDEA-iTECH competition is a clear illustration of this."

”



SYNTHELIS : *The Futures of Protein*

Contact: contact@synthelis.fr

www.synthelis.com